Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT07598214
Recruiting Phase 4

Effect of Diosmin/Hesperidin Combination on Platinum Compounds-Induced Nephropathy in Cancer Patients

NCT07598214 · tracked via the Priya Life Science Egypt tracker
Sponsor
Beni-Suef University
Phase
Phase 4
Started
2025-02-03
Last updated
2026-05-20

Condition(s) studied

Cancer Patients

Investigational drug(s) / intervention(s)

diosmin/hesperdin

diosmin/hesperdin: combination of Diosmin and Hesperidin

Study summary

The current study aims to investigate the protective properties of diosmin/hesperidin on cisplatin-induced nephrotoxicity.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Patients of 18 to 75 year-age must have histologically or cytologically confirmed cancer by the Laboratory of Pathology receiving a platinum compound chemotherapy. Exclusion Criteria: * -History of allergic reactions attributed to drugs in the study. * Pregnant women. * Life expectancy less than 6 months * Inability or unwillingness to comply with research protocols. * Cancer patients with impaired renal function (creatinine clearance \< 50 mL/min) * Preexisting hearing loss. * Patients taking nephrotoxic drugs; and those who have a history of allergic reactions to platinum-containing compounds.

Primary outcome measure(s)

  • serum creatinine level — 6 months following treatment
    Serum creatinine will be measured in mg/dl every 2 weeks during the study period.
  • blood urea level — 6 months following treatment
    blood urea levels will be measured in mg/dl every 2 weeks during the study period.

Trial sites (1)

FacilityCityRegionStatus
Faculty of Medicine Banī Suwayf Egypt Recruiting

More Beni-Suef University trials in Egypt

Manual Diaphragmatic Release Technique on Exercise Capacity and Sleep Quality Recruiting
ComfiJ Versus Conventional Double-J Stent for Ureteral Stent Symptoms Recruiting
A Comparative Study of EMG Biofeedback and Pharmacotherapy for the Treatment of Masticatory Muscle Hyperactivity in Bruxism Patients Starting soon
Growth Hormone and Dehydroepiandrosterone Role in Vitro Fertilization Recruiting
Alveolar Cleft Reconstruction With Cortical-Shells Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07598214 on ClinicalTrials.gov ↗ ← All trials in Egypt